FKBP-12 exhibits an inhibitory activity on calcium oxalate crystal growth in vitro. by Han, In Sook et al.
INTRODUCTION
Deposition of calcium oxalate microcrystal in human body
can be a significant problem and it is recognized that 70-
80% of kidney stones contain calcium oxalate (1). Deposi-
tion of calcium oxalate microcrystal in soft tissues has been
observed in primary hyperoxaluria, chronic renal failure, and
certain small bowel diseases (2, 3, 20). Although pathologic
conditions may arise occasionally when the body fluid is
supersaturated with calcium oxalate, its precipitation is nor-
mally inhibited by a number of low-molecular weight
inhibitors and macromolecular inhibitors (3). Nephrocalcin
was discovered by Nakagawa and his collaborators as a 14
kDa urinary protein, accounting for over 80% of calcium
oxalate crystal and having a growth inhibitory activity in
the normal urine (4). Its molecular characteristics have been
extensively studied (5, 7) and the functionally and biochem-
ically equivalent polypeptides have been isolated from the
urine of various vertebrates (8, 9). Nephrocalcin is, accord-
ingly, considered to be the primary inhibitory protein of
urinary stone formation (3). Nephrocalcin has attracted our
attention due to its potential as a stone-inhibitor agent, and
therefore nephrocalcin cDNA cloning has been attempted in
our laboratory for several years. For this purpose, we have
prepared polyclonal antibodies (10) and used it as a probe in
the screening of human kidney cDNA library. We have iden-
tified a clone whose recombinant peptide was recognized by
the antiserum. The clone encoded a fragment of FK506-bind-
ing protein (FKBP-12) cDNA (11). We report here the
growth inhibitory activity of recombinant FKBP-12 protein
on the formation of calcium oxalate crystal by an in vitro
assay. Furthermore, we evaluated the potential of recombi-
nant FKBP-12 as an anti-urinary stone agent. 
MATERIALS AND METHODS
Tissues
Surgical specimens of adenocarcinoma of the kidney obtain-
ed at the Department of Urology, Medical Center, University
of Chicago were used for the preparation of cDNA libraries.
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FKBP-12 Exhibits an Inhibitory Activity on Calcium Oxalate Crystal
Growth in Vitro
Urolithiasis and calcium oxalate crystal deposition diseases are still significant
medical problems. In the course of nephrocalcin cDNA cloning, we have identi-
fied FKBP-12 as an inhibitory molecule of calcium oxalate crystal growth. gt 11
cDNA libraries were constructed from renal carcinoma tissues and screened for
nephrocalcin cDNA clones using anti-nephrocalcin antibody as a probe. Clones
expressing recombinant proteins, which appeared to be antigenically cross-
reactive to nephrocalcin, were isolated and their DNA sequences and inhibitory
activities on the calcium oxalate crystal growth were determined. One of the
clone  gt 11 #31-1 had a partial fragment (80 bp) of FKBP-12 cDNA as an
insert. Therefore, a full-length FKBP-12 cDNA was PCR-cloned from the  gt 11
renal carcinoma cDNA library and was subcloned into an expression vector. The
resultant recombinant FKBP-12 exhibited an inhibitory activity on the calcium
oxalate crystal growth (Kd=10
-7 M). Physiological effect of the extracellular FKBP-
12 was investigated in terms of macrophage activation and proinflammatory
cytokine gene induction. Extracellular FKBP-12 failed to activate macrophages
even at high concentrations. FKBP-12 seems an anti-stone molecule for the
oxalate crystal deposition disease and recurrent stone diseases.
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Anti-nephrocalcin antiserum
Nephrocalcin was isolated from human urine by Y. Nak-
agawa at the University of Chicago and rabbit anti-human
nephrocalcin antisera were prepared using purified nephro-
calcin preparation. Specificity of antisera was reported pre-
viously (10). This antiserum (R3) has been used for the phage
screening, immunoblotting and immunohistology as a pri-
mary antibody.
Screening and sequencing of nephrocalcin cDNA
Total RNA was prepared according to the method of
Chomczynski and Sacchi (12) from renal carcinoma.  gt 11
cDNA libraries were constructed according to the method
of Young and Davis (13). E. coli strain Y1090 was transfect-
ed with the library, and total 2×104 transfectants replica-
plated on nylon-filters were screened for nephrocalcin-like
peptides using anti-nephrocalcin antiserum. Phage DNA
from a positive clone was extracted by the standard method
(15). The insert was cloned by polymerase chain reaction
(PCR) using  gt 11 forward and reverse primers and sub-
cloned into pTA (Invitrogen, U.S.A.) for the DNA sequenc-
ing by the dideoxy method of Sanger et al.(14).
Recombinant FKBP-12
As the clone designated as #31-1 was consistently posi-
tive by the anti-nephrocalcin antibody screening and the 80
bp insert DNA sequence was identical to FKBP-12 cDNA,
a full length FKBP-12 cDNA was PCR-cloned from a  gt
11 human renal carcinoma cDNA library using the PCR
primers listed in Table 1. The FKBP-12 cDNA was sub-
cloned into pET28a (Novagen, U.S.A.) and E. coli BL21
(DE3) was tranfected by this pET28a-FKBP-12. The BL21
(DE3) transfectant was induced by IPTG and the resultant
recombinant FKBP-12 was purified by Ni-NTA affinity
chromatography specific for His-Tag protein. The molecu-
lar weight of the recombinant FKBP-12 was estimated by
electrophoresis on a sodium dodecylsulfate-polyacrylamide
gel (SDS/PAGE). The electrophoresed protein was further
electroblotted onto a nitrocellulose membrane and probed by
the anti-human nephorcalcin antibody to confirm the initial
antigenic cross-reactivity of FKBP-12 with nephrocalcin. 
Determination of crystal growth inhibitory activity
Affinities of nephrocalcin and the recombinant FKBP-12
to calcium oxalate microcrystal were determined by the spec-
trophotometric method described by Nakagawa et al. (4).
The dissociation constant was determined by the Langmuir-
type isotherm plot with a least-square fit of 1/[I] vs Vo/(Vo-
V), where Vo and V are the initial velocities with and without
nephrocalcin or the recombinant FKBP-12 [I], respectively.
Macrophage activation assay
To determine whether the high concentration of extracellu-
lar FKBP-12 triggers the macrophage activation, the macro-
phage activation assay (16) was carried out. Mouse peritoneal
macrophages were collected and contaminating T cells were
removed using an anti-CD3 antibody (Becton & Dickinson,
U.S.A.), magnetized secondary antibody, and Mac column
(Miltenvi Biotec, U.S.A.). Macrophages were cultured for 24 hr,
and then various concentrations of the recombinant FKBP-
12 (1 to 500  g/mL) were added to each of the cultures. After
6 hr and 16 hr incubation, total RNA were prepared from
each culture and the expressions of proinflammatory genes
(IL-1, TNF- , IL-6, IL-12, and NOS) were analyzed by
reverse transcriptase-PCR (RT-PCR). The primer sequences
used for RT-PCR were obtained from the NCBI GenBank
Database (NIH, U.S.A.) and are shown in Table 1.
cDNA profiles on agarose gel electrophoresis were quan-
tified by the BIO-1D V.96 image analysis software (Vilber
Lourmat, Cedex, France) and data were expressed as the
means±SEM of the percentage of the control level. The
statistical significance of the changes was analyzed and a
difference from the control value of 100 was considered to
be significant when p<0.05 by Student’ s t test.
Expression of FKBP-12 mRNA and protein in the
transfectants
FKBP-12 cDNA was subcloned into a mammalian expres-
sion vector, pcDNA3 (Invitrogen, CA, U.S.A.), and the clone
was designated as pcDNA3-FKBP-12. The pcDNA3-FKBP-
12 cDNA was purified using the Endofree Maxi kit (Qua-
gen, CA, U.S.A.). Mouse fibroblasts, 3LL, were plated onto
6-well tissue culture dishes at 5×105 cells/well and were
grown to a 80% confluency. Then they were transfected with
pcDNA3-FKBP12 cDNA/lipofectamine complex (1  g
DNA/10  L liposome) in a serum-free DMEM at 37℃ for
5 hr in a CO2 incubator. After an additional incubation in a
Name (bp) Sequence (sense primer/antisense primer)
FKBP-12 (329) 5′ -CCATGGGAGTGCAGGTGGAAACC-3′ /
5′ -AGTAAGGTCAAATCTTCGAGGTG-3′
IL-1 (812) 5′ -CTATGGCAACTGTTCCTGAACTC5-3′ /
5′ -TTAGGAAGACACAAATTGCATGGT-3′
IL-12 (652) 5′ -ACATGTGTCAATCACGCTACCTCC-3′ /
5′ -CTTTCAGGCGGAGCTCAGATAGCC-3′
IL-6 (638) 5′ -TATGAAGTTCCTCTCTGCAAGA-3′ /
5′ -CTAGGTTTGCCGACTAGATCTCAA-3′
TNF- (710) 5′ -CCATGAGCACAGAAAGCATGATC-3′ /
5′ -TCACAGAGCAATGACTCTAAA-3′
NOS (440) 5′ -TCAAAGGAGGCCGCATGAGCTTG-3′ /
5′ -TCAGAGCCTCGTGGCTTTGGGCTC-3′
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complete DMEM for 48 hr, the cells were grown in a com-
plete DMEM containing G418 (600  g/mL) (GIBCO, U.S.A.).
Stable transfectant clones were obtained by a continuous selec-
tion by G418. FKBP-12 mRNA and recombinant FKBP-
12 expressions were analyzed by RT-PCR and dot-blot im-
munoassay.
Expression of FKBP-12 mRNA in the cDNA-inoculated
mice
A group (n=15) of ICR mice (8W, male) were inoculated
with 100  g of FKBP-12 cDNA in the quadriceps muscle
or by intraperitoneal injection. Ten to fifty days after the
inoculation, the mice were sacrificed and the macrophage
activation assays (16) were carried out as described above.
Tissues were collected for the in situ evaluation of FKBP-12
transcript expression. In brief, muscle pieces from the FKBP
cDNA-inoculation sites, liver, spleen, kidney, and testis were
cryosectioned at a 8  m thickness to examine the expression
of FKBP-12 mRNA by the in situ RT-PCR described by
Yoon et al. (17). Reverse transcription reaction was performed
at 42℃ for 60 min on the cryosections or macrophage slides
that had been fixed in 4% paraformaldehyde, dehydrated in
ethanol, and treated with protease and DNase. Further in situ
RT-PCR was performed on the same slides using Omnigene
DNA Thermal Cycler (Hybaid, U.K.) and the amplified
cDNA was detected by the DIG DNA-labeling and detec-
tion system (Boehringer Mannheim, Germany).
Possible occurrence of anti-FKBP-12 antibody in the
cDNA-inoculated mice was also estimated by enzyme-linked
immunosorbent assay (ELISA) using the recombinant FKBP-
12 as antigen.
RESULTS
gt 11-HNC clone #31
As stated in the introduction, the original aim of this inves-
tigation was to clone nephrocalcin cDNA from the human
kidney cDNA libraries using a polyclonal anti-human ne-
phrocalcin antiserum as a probe. Specificity of the antiserum
was previously described (10) and the detection limit of ne-
phrocalcin-like protein was determined using purified human
nephrocalcin as the standard in the simulated plaque lifting
experiments.
In this approach, approximately 107 primary clones were
screened from human kidney cDNA libraries. Clones that
seemed to express recombinant proteins reactive to anti-
nephrocalcin antibody were subcloned for rescreening and
plaque purification. 
Over 50 clones have been scrutinized over years and only
one clone designated as #31-1 showed a consistent antigenic
cross-reactivity to nephrocalcin (Fig. 1A). DNA sequence
analysis of this clone (#31-1) and a homology search through
GenBank database revealed that this clone encodes a partial
sequence of FK506-binding protein (FKBP-12) cDNA
(Fig. 1B).
Recombinant FKBP-12 and its inhibitory activity on
calcium oxalate crystal growth
As the clone #31-1 (80 bp) appeared to be identical to the
FKBP-12 cDNA in its sequence from #92 to 171 (Fig. 1B),
we decided to PCR-clone the full-length FKBP-12 cDNA
from a  gt 11 human kidney cDNA library to confirm
whether the recombinant FKBP-12 exhibited an inhibitory
activity on the calcium oxalate crystal growth (Fig. 2). Thus,
the FKBP-12 cDNA obtained was subcloned, after a se-
quence verification, into an E. coli expression vector, pET 28a
(Novagen, U.S.A.). The induced recombinant FKBP-12 was
isolated on a Ni-NTA affinity column and the protein was
analyzed by a SDS/PAGE (Fig. 3A, B). A large amount of
recombinant FKBP-12 was produced in the E. coli BL21
Fig. 1. Isolation and DNA sequence alignment of the clone #31-
1 with FKBP-12. (A) Phage DNA  gt 11 #1 and #31 subclones
were PCR amplified by PCR using  gt 11 forward and reverse
primers and the resultant cDNAs were subcloned into pTA plas-
mid by the TA cloning system. Lanes: (1) #1-1, (2) #1-2, (3) #31-
1, (4) #31-3, (5) #31-5, (6) #31-6, (7) #31-7 plasmid DNAs were
digested by EcoR I and arrows indicate the position of approxi-
mately 100 and 250 bp inserts. The clone #31-1 contained FKBP-
12 cDNA partial sequence as shown in (B). (B) A part of cDNA
sequence of human FK506-binding protein (FKBP) reported by
Maki et al. in 1990 (11) was aligned with cDNA sequence of the
clone #31-1.
M12 3456 7
←100 bp
←250 bp
Clone#31-1 1 tggaaaccatctccccaggagacgggcgcaccttccccaagcgcggccagacctgcgtgg 60
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
FKBP-12   92 tggaaaccatctccccaggagacgggcgcaccttccccaagcgcggccagacctgcgtgg 151
Clone#31-1 61 tgcactacaccgggatgctt 80
IIIIIIIIIIIIIIIIIII
FKBP-12   152  tgcactacaccgggatgctt 171
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(DE3) with a tendency to precipitate at high concentrations.
FKBP-12 and nephrocalcin share a similar molecular size
and their functions are regulated by Ca
++. However, a com-
parison of amino acid composition of nephrocalcin (4, 5) and
FKBP-12 (11) demonstrated that FKBP-12 is not related to
nephrocalcin. Thus, unlike crude preparations, purified the
recombinant FKBP-12 exhibited much reduced immuno-
logical cross-reactivity to anti-nephrocalcin antibody in a dot-
blot immunoassay (Fig. 3C).
We compared the inhibitory activity of the recombinant
FKBP-12 on the calcium oxalate crystal growth with that
of nephrocalcin (Fig. 4). The affinity of nephrocalcin for cal-
cium oxalate crystal has been reported to be between 10-7
and 10-8 M (4, 5). However, the affinity of nephrocalcin in
this study was 4.4×10-7 M and that of FKBP-12 was the
order of 10-7 M. kDa value of uropontin for oxalate crystal
was also reported to be in the range of �10-7 (18).
Physiological function of extracellular FKBP
FKBP proteins were initially purified from the thymus
and spleen, but the subsequent studies at mRNA and protein
levels revealed that they are ubiquitously expressed through-
out the body (11). Immunohistological study also indicated
that nephrocalcin is widely expressed throughout the body
(10), even though there is no evidence that it is a secretory
protein. Although FKBP-12 is a cytoplasmic protein, it is
likely that FKBP-12 is released into the body fluid as a con-
sequence of cell turnover. Therefore it is tempting to specu-
late that plasma FKBP-12 might serve as an inhibitor of
calcium oxalate crystal growth in vivo together with nephro-
calcin and others.
We therefore decided to investigate the physiological effect
of high concentrations of FKBP-12 on the macrophage acti-
vation. Mouse peritoneal the macrophages were cultured in
the presence of various concentrations of the recombinant
FKBP-12 and the expressions of inflammation-related gene
transcripts (IL-1, TNF- , IL-6, IL-12, and NOS) were exam-
ined with total RNAs from the macrophages. In comparison
A C B
Fig. 3. Characterization of recombinant FKBP-12. (A) FKBP-12 cDNA was subcloned into an E. coli expression vector, pET 28a and
the recombinant FKBP protein was induced by IPTG for 3 hr (0, 1, 2, and 3 hr). MW: lysozyme (14 kDa), F: recombinant FKBP-12 (17
kDa: the recombinant protein contains an extra peptide sequence that includes His-Tag, T7-Tag, and others). (B) Approximate
molecular weight of the recombinant FKBP-12 was estimated by SDS-PAGE. MW: protein molecular weight marker, F: FKBP (M, 17
kDa monomer, D, 34 kDa dimer). Recombinant FKBP-12 with His-Tag sequence was purified by the Ni-NTA affinity column chro-
matography and the concentrated FKBP-12 exhibited a tendency to aggregate and precipitate. (C) Immunoblot of nephrocalcin (N)
and recombinant FKBP-12 (F) by a rabbit anti-nephrocalcin antiserum and normal serum. (a) normal serum control (b) and (c) FKBP-
12 (50  g) and purified nephrocalcin (1 ng N & 50 ng F) probed by anti-nephrocalcin antiserum.
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Fig. 2. FKBP-12 cDNA. A full-length FKBP-12 cDNA was cloned
by PCR from a  gt 11 cDNA library prepared from human ade-
nocarcinoma of the kidney.
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with the unstimulated control, the recombinant FKBP-12
did not enhance the expression of proinflammatory cytokine
genes (Fig. 5). Therefore, the possibility of macrophage acti-
vation by FKBP-12 was ruled out even at high concentra-
tions.
Possible application of recombinant FKBP-12 as an
anti-stone agent
If extracellular FKBP serves as an physiological inhibitor
of oxalate crystal growth, a continuous release of FKBP by
infusion or by inoculation of FKBP cDNA might be effective
in the treatment of oxalate microcrystal deposition disease.
Therefore, FKBP-12 cDNA was subcloned into a mammalian
expression vector, pcDNA3, to obtain a long-term continuous
release model for FKBP-12. The anti-nephrocalcin antiserum
used for the initial plaque screening and im-munoblotting
of the purified recombinant FKBP-12 recognized both nephro-
calcin and FKBP-12 in the body fluid as well as in any tis-
sues; an example is shown in Fig. 6A. However, quantitative
monitoring of the recombinant FKBP-12 with anti-nephro-
calcin antiserum was difficult.
Nevertheless, pcDNA3-FKBP-12-transfected mouse fibro-
blast culture was established as a simulation model. Releases
of FKBP-12 mRNA (Fig. 6B) and the recombinant FKBP-
12 (Fig. 6C) into the supernatant of transfectant cultures were
demonstrated by RT-PCR and dot-blot immunoassay, respec-
tively.
As a simulation of FKBP-12 gene therapy for the treatment
of oxalate crystal deposition disease, pcDNA3-FKBP-12 DNA
was inoculated to a group of mice. Ten to fifty days after the
inoculation, the expression of FKBP-12 transcripts at the
inoculation sites was analyzed by in situ RT-PCR (Fig. 7A).
Our previous experience (17) showed that mRNA expression
begins on the 10th day and lasts at least several months. 
To investigate the macrophage activation by the extracel-
lular FKBP in the pcDNA3-FKBP-12-inoculated mice, the
expressions of proinflammatory gene transcripts in the peri-
toneal macrophages were examined by RT-PCR. As shown
in Fig. 7B, FKBP-12 cDNA-inoculated mice did not show
any evidence of macrophage activation or histologicaly abnor-
mal finding in any tissues in this series of experiments (data
not presented). Furthermore, anti-FKBP-12 antibody syn-
thesis was not induced. Therefore, we concluded that the con-
6 hr 16 hr 0 hr
M12345 6 M12345 6 M12345 6
Fig. 5. Effects of extracellular FKBP-12 on the macrophage activation. (A) Mouse peritoneal macrophages were exposed to a various
concentrations of the recombinant FKBP-12, and the total RNAs were prepared at the time points of 0, 6 hr and 16 hr incubation. The
induction of various cytokine gene transcripts in the macrophages were analyzed by RT-PCR and agarose gel electrophoresis (A, 0 hr,
B, 6 hr, C, 16 hr: cultured in the presence of rFKBP-12, M: 100 bp ladder DNA size marker, 1: GAPDH, 2: IL-1, 3: TNF- , 4: IL-6, 5: IL-
12, 6: NOS). cDNA gel images were quantified and compared by cDNA densities of different sampling times and no significant differ-
ences were noticed from those of control values. The gel images shown here are from a typical experiment that was repeated three
times with nearly identical results.
A B C
Fig. 4. Langmuir-type isotherm showing an inhibition of calcium
oxalate crystal growth with increasing concentrations of (a)
recombinant FKBP-12 (Kd=1×10
-7 M) and (b) nephrocalcin
(Kd=4.4×10
-7 M).
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tinuous release of FKBP-12 by infusion or the FKBP-12
cDNA therapy may be a viable option for the treatment of
calcium oxalate microcrystal deposition disease. 
DISCUSSION
The advent of new technologies for urinary stone removal,
such as extracorporeal shock wave lithotripsy, has facilitated
stone removal and reduced the morbidity associated with
urinary stone diseases. Nevertheless, the recurrence rate of the
disease in the industrialized countries has never been reduced
(1), and the incidence of urinary stones in Korea has been
steadily increasing since the late 1970s (19). Numerous com-
plications arising from the chronic glomerulonephritis have
a common origin of calcium oxalate microcrystal deposition,
which seems to trigger inflammation through an in situ com-
plement activation. Blood calcium oxalate supersaturation has
been reported in such patients and correlated with the deposi-
tion of calcium oxalate microcrystal in kidney, myocardium,
blood vessels, and other tissues. The number of patients with
chronic glomerulonephritis receiving peritoneal dialysis or
Fig. 7. FKBP-12 cDNA inoculation and macrophage activation. (A) Mice were inoculated with pcDNA3-FKBP-12 cDNA intramuscular-
ly, and the FKBP-12 mRNA expression was demonstrated on day 10 by the in situ RT-PCR technique in the muscular thin sections at
the inoculation sites (control: uninoculated muscle/ FKBP-12: 100  g pcDNA3-FKBP-12 cDNA inoculated muscle, arrow indicates the
presence of FKBP-12 mRNA). Alkaline phosphatase staining of digoxigenin-labeled cDNA, ×400. (B) Mice were inoculated with
FKBP-12 cDNA intraperitoneally, and the peritoneal macrophages were collected 10 days after the inoculation. Total RNAs were pre-
pared and the induction of various cytokine gene transcripts was analyzed by RT-PCR and agarose gel electrophoresis (control:
macrophages from uninoculated mice, FKBP-12 cDNA: macrophages from FKBP-12 cDNA - inoculated mice, M: 100 bp ladder DNA
size marker, 1: GAPDH, 2: IL-1, 3: TNF- , 4: IL-6, 5: IL-12, 6: NOS). As the quantified cDNA gel image data did not reveal any signifi-
cant differences from those of control values, the gel images shown here are from a typical experiment that was repeated twice with
nearly identical results.
M123456M123456
Control
Control
FKBP-12 cDNA
FKBP-12 cDNA A B
A B C
Fig. 6. Immunological detection of FKBP-12 by anti-nephrocalcin antiserum. (A) Immunohistological demonstration of FKBP-12 - as well
as nephrocalcin-expressing cells in the renal tubules (Immunoperoxidase method, ×400). (B) Demonstration of the FKBP-12 mRNA in
the pcDNA3-FKBP-12 - transfected mouse fibroblasts, 3LL, by the RT-PCR technique. (C) Demonstration of the recombinant FKBP-12
in the concentrated culture supernatants from the transfectant 3LL by the dot blot immunoassay. Each spot contained approximately
100 ng of each protein (1) recombinant FKBP-12 100-fold concentrated from the transfectant culture supernatant, (2) fetal calf serum,
(3) Tamm-Horsfall protein, (4) bovine serum albumin (5) concentrated human urinary proteins from which human nephrocalcin was puri-
fied, (6) human nephrocalcin, (7) mouse nephrocalcin, (8) bovine nephrocalcin.
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hemodialysis has been increasing (21). Furthermore, both
hyperoxalemia resulting from various conditions, such as
hereditary oxalate overproduction states (22), or from drugs
and toxins that increase oxalate production and hyperoxaluria
in various intestinal diseases or following ileal resection or
jejunoileal bypass surgery have obvious potential to induce
calcium oxalate crystal deposition disease.
The mechanisms of urinary stone formation and microcrys-
tal deposition are complex and have not been fully explained
yet. Therefore, efforts should be made to elucidate the mech-
anisms and to apply the knowledge to the reduction of uri-
nary stone diseases, as well as to the alleviation of various
syndromes arising from chronic glomerulonephritis.
According to the currently held viewpoints (3), urinary
stone formation and tissue deposition of calcium oxalate
microcrystals are directly related to the supersaturation of the
body fluid with calcium and oxalate. Furthermore, macro-
molecular inhibitors of crystal growth and aggregation, such
as nephrocalcin (4), osteopontin (18), and mannan-binding
lectin (MBL)-associated plasma protein (23), are crucial in
the pathogenesis.
Nakagawa and his collaborators’ discovery of nephrocalcin
(4) and their seminal works on analytical approaches (2, 5-7)
stimulated much of academic interests on the urinary stone
research. Their detailed analyses on the nephrocalcin isoforms
and molecular abnormality of the urinary stones of nephroli-
thiasis (5, 6) suggested genetic background of nephrolithiasis.
Furthermore, application of molecular biological techniques
facilitated the identification of new inhibitors of calcium
oxalate microcrystals (18, 23). Although nephrocalcin was the
prototype and undoubtedly the best-studied inhibitor of
calcium oxalate crystal growth under inorganic conditions,
it is becoming increasingly apparent that its activity is not
unique: many more proteins having similar properties will
continue to be identified. 
Here we described the inhibitory activity of FKBP-12 on
the calcium oxalate crystal growth, which was not signifi-
cantly different from that reported for nephrocalcin. Even
with the best-purified preparations, nephrocalcin exhibited
a heterogenecity on a TSK 2000SW HPLC column, and
the dissociation constant of each peak fraction ranged from
4.4×10-7 M to 1.0×10-8 M (4-9). Kd value of FKBP-12
was 1×10-7 M (Fig. 4), as it was in uropontin (18).
FKBP-12 molecule does not share any structural similarity
with nephrocalcin in terms of GLA and surface-active pro-
perty (6, 7), and the structural basis for the calcium oxalate crys-
tal binding of FKBP-12 has not been elucidated yet. FKBP-
12 is rich in acidic amino acids (mostly glu) in its C-terminal
region, and these residues may provide an ideal electrostatic
environment for Ca
++ binding. If the Ca
++ chelation is the only
mechanism of calcium oxalate crystal growth inhibitory activi-
ty, the Kd value of FKBP-12 for Ca
++ is too low for the inhi-
bition. Thus, it seems likely that FKBP-12 inhibits the crys-
tal growth by interacting with crystals. FKBP-12 is known
to interact with structurally unrelated diverse molecules, such
as FK506, rapamycin, and many other synthetic ligands (24).
To our knowledge, FKBP-12 is the first immunophilin
shown to inhibit the calcium oxalate microcrystal formation
by in vitro studies. Functional studies (11, 24-28) have demon-
strated that FKBP-12 is a rotamase, a receptor for immuno-
suppresive drugs as well as neurotrophic ligands. Structural
basis for the FKBP binding to FK506 and rapamycin was
elucidated by Schreiber and his collaborators (27). To explain
FKBP-12 as a calcium oxalate microcrystal inhibitory mole-
cule, structural basis for the binding of FKBP-12 to calcium
oxalate should be elucidated by crystallographic studies in
the future.
Calcium oxalate deposition occurs in tissues of patients
with renal failure who are on chronic hemodialysis or peri-
toneal dialysis (21). FKBP-12 and nephrocalcin are small
proteins, which can be lost from those patients through the
diseased kidney or during dialysis. An infusion or continuous
release of FKBP-12 by gene therapy might be effective in
such clinical situations. The extracellular FKBP-12 did not
appear to cause macrophage activation (Fig. 5, 7). Therefore,
the FKBP-12 infusion therapy or gene therapy could be a
viable option for those patients. 
In conclusion, we have shown that FKBP-12 exhibited an
inhibitory activity on the calcium oxalate crystal growth and
that FKBP-12 may be potential therapeutic agent in clinical
conditions resulting from the calcium oxalate microcrystal
deposition.
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